A detailed history of Bank Of America Corp transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 547,716 shares of ITCI stock, worth $39.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
547,716
Previous 562,325 2.6%
Holding current value
$39.7 Million
Previous $38.9 Million 3.6%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$64.76 - $79.84 $946,078 - $1.17 Million
-14,609 Reduced 2.6%
547,716 $37.5 Million
Q1 2024

May 15, 2024

BUY
$64.37 - $75.65 $5.09 Million - $5.98 Million
79,031 Added 16.35%
562,325 $38.9 Million
Q4 2023

Feb 14, 2024

SELL
$46.37 - $73.65 $3.33 Million - $5.29 Million
-71,825 Reduced 12.94%
483,294 $34.6 Million
Q2 2023

Aug 14, 2023

BUY
$54.67 - $66.44 $15 Million - $18.2 Million
273,991 Added 97.46%
555,119 $35.2 Million
Q1 2023

May 12, 2023

BUY
$43.8 - $56.99 $4.59 Million - $5.97 Million
104,718 Added 59.36%
281,128 $15.2 Million
Q4 2022

Feb 10, 2023

BUY
$44.07 - $54.45 $186,195 - $230,051
4,225 Added 2.45%
176,410 $9.34 Million
Q3 2022

Nov 14, 2022

SELL
$42.7 - $59.99 $578,798 - $813,164
-13,555 Reduced 7.3%
172,185 $8.01 Million
Q2 2022

Aug 12, 2022

SELL
$43.0 - $65.64 $121,260 - $185,104
-2,820 Reduced 1.5%
185,740 $10.6 Million
Q1 2022

May 16, 2022

BUY
$38.74 - $62.09 $2.64 Million - $4.23 Million
68,112 Added 56.55%
188,560 $11.5 Million
Q4 2021

Feb 08, 2022

BUY
$35.2 - $53.42 $1.33 Million - $2.01 Million
37,644 Added 45.46%
120,448 $6.31 Million
Q3 2021

Nov 15, 2021

SELL
$28.72 - $42.49 $121,370 - $179,562
-4,226 Reduced 4.86%
82,804 $3.09 Million
Q2 2021

Sep 13, 2021

BUY
$29.3 - $44.5 $2.55 Million - $3.87 Million
87,030 New
87,030 $3.55 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $6.84B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.